Cellectar Biosciences Inc (CLRB)

Form 3 - Initial statement of beneficial ownership of securities

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness

Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting

Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of...

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report

Form 8-K - Current report

Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 4 - Statement of changes in beneficial ownership of securities

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors